GDC-0879 - Moligand™, ≥96% , Inhibitor of B-Raf proto-oncogene; serine/threonine kinase, CAS No.905281-76-7, Inhibitor of B-Raf proto-oncogene; serine/threonine kinase

CAS: 905281-76-7 Cat. No.: G127893 Formula: C19H18N4O2 Peso molecolare: 334.37
Disponibile su ordine
QUALITÀ & PUREZZA Moligand™ ? Moligand™ — Aladdin's line of ligands and bioactive small molecules. Use for receptor, pathway, and binding studies needing defined small-molecule tools. ≥96%
Synonyms
2,3-dihydro-5-(1-(2-hydroxyethyl)-3-(4-pyridinyl)-1h-pyrazol-4-yl)-1h-inden-1-one oxime|2-{4-[(1e)-1-(Hydroxyimino)-2,3-Dihydro-1h-Inden-5-Yl]-3-(Pyridin-4-Yl)-1h-Pyrazol-1-Yl}ethanol|Naxonate hydrotrope|2-[4-[(1E)-1-hydroxyimino-2,3-dihydroinden-5-yl]-3-pyridin-4-ylpyrazol-1-yl]ethanol|5-(1-(2-Hydroxyethyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime|2,3-Dihydro-5-[1-(2-hydroxyethyl)-3-(4-pyridinyl)-1H-pyrazol-4-yl]-1H-inden-1-one oxime|GDC 0879|2-Mercaptobenzothiazole, sodium salt|2-{4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-pyridin-4-yl-1H-pyrazol-1-yl}ethanol;(E)-5-(1-(2-hydroxyethyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2,3-dihydroinden-1-one oxime|5-(1-(2-Hydroxyethyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2,3-dihydroinden-1-one oxime|GDC0879|GDC-0879|(E)-5-(1-(2-hydroxyethyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime|1H-Inden-1-one, 2,3-dihydro-5-(1-(2-hydroxyethyl)-3-(4-pyridinyl)-1H-pyrazol-4-yl)-, oxime|1H-Inden-1-one, 2,3-dihydro-5-(1-(2-hydroxyethyl)-3-(4-pyridinyl)-1H-pyrazol-4-yl)-, oxime, (1E)-|5-[1-(2-Hydroxy-ethyl)-3-pyridin-4-yl-1H-pyrazol-4-yl]-indan-1-one oxime|(E)-5-(1-(2-hydroxyethyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2,3-dihydroinden-1-one oxime|(E)-5-(1-(2-Hydroxyethyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
★
Dimensione
Germania (EU)
USA*
Prezzo
Qtà
2mg
G127893-2mg
—
3 Disponibile

84,08€

126,60€
Salva 42,52 € (33.58%)
5mg
G127893-5mg
—
3 Disponibile

183,01€

274,99€
Salva 91,98 € (33.45%)
25mg
G127893-25mg
—
3 Disponibile

686,29€

1.029,92€
Salva 343,62 € (33.36%)
100mg
G127893-100mg
—
2 Disponibile

2.196,16€

3.294,72€
Salva 1.098,56 € (33.34%)
Enter a quantity for the sizes you want to add.

Specifiche

Sinonimi
2,3-dihydro-5-(1-(2-hydroxyethyl)-3-(4-pyridinyl)-1h-pyrazol-4-yl)-1h-inden-1-one oxime | 2-{4-[(1e)-1-(Hydroxyimino)-2,3-Dihydro-1h-Inden-5-Yl]-3-(Pyridin-4-Yl)-1h-Pyrazol-1-Yl}ethanol | Naxonate hydrotrope | 2-[4-[(1E)-1-hydroxyimino-2,3-dihydroinden-5-yl]-3-pyridin-4-ylpyrazol-1-yl]ethanol | 5-(1-(2-Hydroxyethyl)-3-(pyridin-4-yl)-1H-py Mostra altro
Specifiche e purezza
Moligand™, ≥96%
Meccanismi biochimici e fisiologici
GDC-0879 is an B-Raf inhibitor( EC50 = 0.75 μM).Potent and selective B-Raf inhibitor (IC 50 =\xa00.13 nM against purified V600E enzyme). Inhibits cellular pERK (IC 50 = 63 nM). Blocks Raf/MEK/ERK signaling in B-Raf V600E mutant cell lines.
Condizioni di conservazione di stoccaggio
Store at -20°C
Spedito in
Ice chest + Ice pads
Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.
Grado
Moligand™
Tipo di azione
INHIBITOR
Meccanismo d'azione
Inhibitor of B-Raf proto-oncogene; serine/threonine kinase
Nota
Refer to SDS for further information Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Purezza
≥96%
Nomi e identificatori
Pubchem Sid
Pubchem Sid Url
https://pubchem.ncbi.nlm.nih.gov/substance/504766673
SMILES
C1CC(=NO)C2=C1C=C(C=C2)C3=CN(N=C3C4=CC=NC=C4)CCO
IUPAC Name
2-[4-[(1E)-1-hydroxyimino-2,3-dihydroinden-5-yl]-3-pyridin-4-ylpyrazol-1-yl]ethanol
InChIKey
DEZZLWQELQORIU-RELWKKBWSA-N
InChI
1S/C19H18N4O2/c24-10-9-23-12-17(19(21-23)13-5-7-20-8-6-13)15-1-3-16-14(11-15)2-4-18(16)22-25/h1,3,5-8,11-12,24-25H,2,4,9-10H2/b22-18+
Isomeri SMILES
C1C/C(=N\O)/C2=C1C=C(C=C2)C3=CN(N=C3C4=CC=NC=C4)CCO
Peso molecolare
334.37
Reaxy-Rn
12685506
Reaxys-RN_link_address
https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=12685506&ln=

Dati avanzati

Taxonomic Classification

Taxonomy Tree

KingdomOrganic compounds
SuperclassBenzenoids
ClasseIndanes
SubclassNot available
Intermediate Tree Nodes Not available
Direct ParentIndanes
Alternative Parents Pyridines and derivatives  Pyrazoles  Ketoximes  Heteroaromatic compounds  Azacyclic compounds  Alkanolamines  Primary alcohols  Organopnictogen compounds  Hydrocarbon derivatives  
Molecular FrameworkAromatic heteropolycyclic compounds
Substituents Indane - Pyridine - Azole - Ketoxime - Pyrazole - Heteroaromatic compound - Organoheterocyclic compound - Alkanolamine - Azacycle - Organic oxygen compound - Primary alcohol - Organooxygen compound - Organonitrogen compound - Organic nitrogen compound - Alcohol - Hydrocarbon derivative - Organopnictogen compound - Aromatic heteropolycyclic compound
DescrizioneThis compound belongs to the class of organic compounds known as indanes. These are compounds containing an indane moiety, which consists of a cyclopentane fused to a benzene ring.
External Descriptors pyrazoles - primary alcohol - pyridines - ring assembly - indanes - ketoxime
Struttura 3D
Modello di struttura chimica interattiva





Obiettivi associati (umani)
RAF1 Tclin RAF proto-oncogene serine/threonine-protein kinase (2 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
BRAF Tclin Serine/threonine-protein kinase B-raf (8 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
ABL1 Tclin Tyrosine-protein kinase ABL (18331 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
EGFR Tclin Epidermal growth factor receptor erbB1 (33727 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
INSR Tclin Insulin receptor (5558 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ERBB2 Tclin Receptor protein-tyrosine kinase erbB-2 (7851 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PDGFRB Tclin Platelet-derived growth factor receptor beta (5195 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
IGF1R Tclin Insulin-like growth factor I receptor (8605 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KIT Tclin Stem cell growth factor receptor (10667 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CSNK2A1 Tchem Casein kinase II alpha (3512 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DAPK3 Tchem Death-associated protein kinase 3 (2108 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MAPK11 Tchem MAP kinase p38 beta (2785 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
LCK Tclin Tyrosine-protein kinase LCK (9212 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MAPK14 Tchem MAP kinase p38 alpha (12866 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
GSK3B Tclin Glycogen synthase kinase-3 beta (11785 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PRKACB Tchem cAMP-dependent protein kinase beta-1 catalytic subunit (589 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MAP2K6 Tchem Dual specificity mitogen-activated protein kinase kinase 6 (1284 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MYLK Tchem Myosin light chain kinase, smooth muscle (1267 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CSNK1G1 Tchem Casein kinase I gamma 1 (2496 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FGFR2 Tclin Fibroblast growth factor receptor 2 (3405 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FGFR1 Tclin Fibroblast growth factor receptor 1 (9149 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
STK3 Tchem Serine/threonine-protein kinase MST2 (3069 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CSNK1D Tchem Casein kinase I delta (4546 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MAP2K5 Tchem Dual specificity mitogen-activated protein kinase kinase 5 (650 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CAMK2B Tchem CaM kinase II beta (1626 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SRC Tclin Tyrosine-protein kinase SRC (10310 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MAP2K3 Tchem Dual specificity mitogen-activated protein kinase kinase 3 (632 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CHEK2 Tchem Serine/threonine-protein kinase Chk2 (4015 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PDPK1 Tchem 3-phosphoinositide dependent protein kinase-1 (3758 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PRKAA2 Tchem AMP-activated protein kinase, alpha-2 subunit (1328 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AKT2 Tchem Serine/threonine-protein kinase AKT2 (4301 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AKT3 Tchem Serine/threonine-protein kinase AKT3 (3157 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CHUK Tchem Inhibitor of nuclear factor kappa B kinase alpha subunit (3170 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
IKBKB Tchem Inhibitor of nuclear factor kappa B kinase beta subunit (5554 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DAPK2 Tchem Death-associated protein kinase 2 (740 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AURKB Tchem Serine/threonine-protein kinase Aurora-B (6805 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
RPS6KA4 Tchem Ribosomal protein S6 kinase alpha 4 (2104 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ROCK1 Tclin Rho-associated protein kinase 1 (4723 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PIM1 Tchem Serine/threonine-protein kinase PIM1 (9629 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PKN2 Tchem Protein kinase N2 (1991 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CSK Tchem Tyrosine-protein kinase CSK (2395 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
JAK3 Tclin Tyrosine-protein kinase JAK3 (8349 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
RPS6KA5 Tchem Ribosomal protein S6 kinase alpha 5 (3355 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PRKCE Tchem Protein kinase C epsilon (1520 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PRKD3 Tchem Protein kinase C nu (2315 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PRKCI Tchem Protein kinase C iota (2821 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PRKD1 Tchem Protein kinase C mu (1904 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
RAF1 Tclin Serine/threonine-protein kinase RAF (4169 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SYK Tclin Tyrosine-protein kinase SYK (7372 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PLK1 Tchem Serine/threonine-protein kinase PLK1 (28605 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ITK Tclin Tyrosine-protein kinase ITK/TSK (3699 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
JAK1 Tclin Tyrosine-protein kinase JAK1 (8569 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Obiettivi associati (non umani)
Cdk4 Cyclin-dependent kinase 4 (3 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PIK3CA PI3-kinase p110-alpha subunit (51 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Prkcd Protein kinase C delta (192 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mapk1 MAP kinase ERK2 (650 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Hdac6 Histone deacetylase 6 (222 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Fgfr4 Fibroblast growth factor receptor 4 (138 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Fgfr3 Fibroblast growth factor receptor 3 (21 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Camk2g CaM kinase II gamma (1 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Tec Tyrosine-protein kinase TEC (25 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Hsf1 Heat shock factor protein 1 (5445 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
rep Replicase polyprotein 1ab (378 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
pknB Serine/threonine-protein kinase pknB (356 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CDPK1 Calcium-dependent protein kinase 1 (793 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CRK2 Cell division control protein 2 homolog (194 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Meccanismi d'azione
Certificati (CoA, COO, BSE/TSE e tabella di analisi)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

4 results found

Lot NumberCertificate TypeDataOggetto
C23081327C23081327Certificate of AnalysisSep 01, 2026 G127893
C23081384C23081384Certificate of AnalysisSep 01, 2026 G127893
C23081388C23081388Certificate of AnalysisSep 01, 2026 G127893
C23081398C23081398Certificate of AnalysisSep 01, 2026 G127893
Proprietà chimiche e fisiche
SolubilitàDMSO 67 mg/mL Water <1 mg/mL Ethanol 5 mg/mL
Peso molecolare334.400 g/mol
XLogP31.700
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count5
Rotatable Bond Count4
Exact Mass334.143 Da
Monoisotopic Mass334.143 Da
Topological Polar Surface Area83.500 Ų
Heavy Atom Count25
Formal Charge0
Complexity480.000
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count1
Undefined Bond Stereocenter Count0
The total count of all stereochemical bonds1
Covalently-Bonded Unit Count1
Domande frequenti e articoli
Calcolatori di soluzioni
Recensioni

Recensioni dei clienti

Application Protocols

No vendor-validated application protocols are provided in this listing. The following are general, non-product-specific guidelines for bioactive small molecules in pathway studies.

General cell-based assay protocol (example framework):

  • Prepare a 10 mM DMSO stock (confirm solubility for your lot). Aliquot and store at −20 °C.
  • Plate cells to desired density. After attachment, treat with a half-log dilution series (e.g., 10 points) with constant DMSO across all wells (≤0.1–0.2% v/v typical).
  • Incubate for 1–4 h for acute signaling readouts or 24–72 h for viability/proliferation endpoints, as appropriate.
  • Quantify pathway modulation via phospho-specific antibodies or reporter assays. Include vehicle controls and, where possible, an orthogonal positive control.

General biochemical assay protocol (example framework):

  • Assemble kinase reaction mix at Km(ATP) with substrate peptide/protein.
  • Add compound at serially diluted concentrations; initiate reaction with ATP.
  • Incubate under linear conditions and detect product formation by luminescence/fluorescence/mass shift.
  • Fit concentration–response to obtain IC50; perform counter-screens for assay interference.

Important: These are illustrative outlines only. Optimize parameters (cell line, exposure time, buffer composition, detection modality) for your specific system. No specific protocols are validated for this item.

Biological Roles

Context (literature/general):

  • GDC-0879 is described in the literature as a small-molecule kinase pathway modulator, commonly associated with studies of RAF-dependent signaling within the MAPK cascade (RAF–MEK–ERK). Compounds of this class are used to perturb intracellular phosphorylation networks to elucidate pathway wiring, feedback, and resistance mechanisms.

Typical research deployments:

  • Enzymology: Determination of IC50/Ki against purified kinase domains, time-dependence, and ATP-competitive behavior via kinetic assays.
  • Cell signaling: Western blot/ELISA or phospho-specific readouts (e.g., pERK levels) after short compound exposures to quantify pathway inhibition dynamics.
  • Systems biology: Dose–response profiling across cell panels to map differential sensitivity and pathway biomarkers; integration with transcriptomic/proteomic endpoints to study adaptive responses.

Mechanistic considerations (general):

  • Kinase inhibitors often exploit hinge-binding H-bonding and hydrophobic interactions in the ATP pocket. Selectivity is influenced by gatekeeper residues and activation segment conformation; literature on GDC-0879 discusses RAF family selectivity, which should be verified from authoritative sources before experimental design.

Important note for this listing:

  • No target specificity or potency data are provided in the product data. Treat all target-related statements above as literature context only. For this specific item/lot, confirm target profile using your assays or consult peer-reviewed sources and the CoA.
Buffer Applications

This item is a bioactive small molecule rather than a buffering agent. As such, it does not constitute a buffer system and has no defined buffering range.

Practical notes for assay buffers (general guidance):

  • Use your assay’s validated buffer (e.g., HEPES, Tris, or phosphate systems at pH 7.2–7.5 for many kinase assays), adding compound from DMSO stocks to a final DMSO content typically ≤0.1–0.2% v/v.
  • Include vehicle controls matching the highest DMSO concentration used.
  • For cell-based assays, serum content and protein binding can reduce free concentration; consider serum-free pre-incubation windows or measure unbound fraction when quantitative pharmacology is required.

Conclusion: No specific buffer formulation is associated with this product; follow assay-specific buffer recommendations and validate compound compatibility empirically.

Green Alternatives

As a bioactive screening compound, the primary “green” lever is solvent and workflow selection rather than replacing the molecule itself.

Greener solvent choices for stock preparation (general):

  • Prefer aqueous-buffered systems with minimal DMSO carryover (≤0.1% v/v) when compatible with solubility and assay biology.
  • Consider ethanol (EtOH) over DMF/NMP where possible, balancing volatility and biological tolerance.
  • Use cyclodextrin-based solubilizers (e.g., 2-hydroxypropyl-β-cyclodextrin) to reduce organic solvent content in some in vitro contexts.

Process improvements:

  • Miniaturize assays (384/1536-well) to cut solvent and compound consumption.
  • Employ acoustic dispensing to reduce DMSO volumes and plastic waste.
  • Consolidate analytical runs and use shorter LC methods to reduce acetonitrile consumption.

Comparison snapshot (general guidance):

  • DMSO: Excellent solubility and miscibility; moderate environmental impact; widely accepted in biological assays.
  • EtOH: Renewable origin routes exist; higher volatility; lower solvency for many kinase inhibitors.
  • PEG400/citrate buffer systems: Low volatility and reduced hazard; viscosity and biological effects must be validated.

Waste and lifecycle:

  • Segregate halogen-free organic waste and minimize rinse volumes by using dedicated, low-adsorption plasticware for hydrophobic compounds.
  • Where feasible, implement compound management systems (low-temperature, inert headspace, capped microtubes) to extend shelf life and reduce resynthesis/reordering footprints.
Pharmaceutical Uses

Scope of use for this catalog item:

  • For research use only (product data). Not for human or veterinary use. No clinical or diagnostic applications are supported.

Roles in pharmaceutical R&D (general, non-clinical):

  • Reference material: Utilized as a pathway probe or benchmark control in preclinical discovery assays (e.g., enzymatic inhibition, cellular signaling modulation) to calibrate assay windows and compare novel analogs.
  • Screening library member: Included in focused or diverse libraries to enable phenotypic or target-based screening campaigns; aids in establishing positive-control conditions and validating assay sensitivity.
  • Analytical standard (internal use): May be employed to develop/validate LC–MS bioanalytical methods (selectivity, recovery, stability) in non-GLP research contexts.

Regulatory/pharmacopeial status:

  • Not a pharmacopeial article; no compendial monograph. Any use in regulated studies requires independent qualification and documentation.

Formulation development note:

  • If used in formulation research models (non-clinical), typical vehicles include DMSO/PEG400/saline or ethanol/PEG400/saline blends. Such applications require toxicity and stability vetting; none are specified for this item.

All statements above are general to bioactive small molecules and are not product-specific specifications.

Physical Properties

Item-specific physico-chemical specifications are not provided in this listing. Do not treat any value below as a specification; consult the CoA/SDS for definitive data.

  • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.
  • Melting point (literature): Not readily standardized across sources; verify experimentally for your lot.
  • Boiling point: Not applicable/reported for a non-volatile solid of this class; typically decomposes before boiling (literature, general for kinase inhibitors).
  • Density: Not specified for this item; refer to CoA/Spec Sheet.
  • Solubility (general guidance, literature): Many RAF/kinase inhibitors are sparingly soluble in water and readily soluble in DMSO; working stocks are commonly prepared at 10–50 mM in anhydrous DMSO and diluted into assay buffers at ≤0.1–0.2% DMSO final. Actual solubility for this item must be verified empirically.
  • logP/logD, pKa, refractive index: Not specified for this item; consult literature databases (e.g., PubChem CID 11717001) and confirm with internal measurements if needed.

Practical notes (general):

  • For analytical work, determine UV–Vis profile of your lot to support HPLC detection; many heteroaromatic kinase inhibitors absorb strongly 250–330 nm (literature, general trend).
  • Hygroscopicity and polymorphism can affect measured properties; record handling conditions to ensure reproducibility.
Quality and Grades
  • Grade/Purity: Moligand™ (product data)

What Moligand™ implies (general description):

  • Moligand™ denotes a bioactive small-molecule suitable for screening and chemical biology. Such offerings are commonly qualified by identity (LC–MS, NMR) and purity by chromatographic methods. Exact acceptance criteria and purity percentage for this specific item are Not specified for this item; refer to CoA/Spec Sheet.

Analytical expectations (general best practices for this class):

  • Identity: Verify with high-resolution MS (if available) and diagnostic 1H/13C NMR peaks.
  • Purity: HPLC/UPLC purity often ≥95% for screening collections, but treat this only as a general benchmark; rely on the item’s CoA for the actual value.
  • Residual solvents/inorganics: Not specified for this item; refer to CoA/Spec Sheet.
  • Counter-ions/salt form: Not specified for this item; verify free base vs. salt form before calculating stock concentrations.

Batch-to-batch considerations:

  • Lot-specific polymorph or solvate content may influence solubility and assay performance. Re-validate critical assays upon lot change.

Documentation:

  • Retain the CoA, SDS, and any analytical traces provided with the shipment. For regulated workflows, append your in-house requalification data to the batch record.
Reaction and Applications

This product is supplied as a bioactive small molecule for research use, not as a synthetic reagent. Consequently, classical synthetic reaction applications (e.g., cross-couplings, condensations) are not the primary focus.

Applications (research use, literature/general):

  • Chemical biology tool: GDC-0879 is reported in the literature as a kinase pathway probe, frequently associated with RAF–MEK–ERK signaling studies. Such tools are used to interrogate pathway dependence, validate targets, and benchmark assay performance. Verify the precise target profile and potency for your lot against authoritative literature and your in-house assays.
  • Assay development: Serves as a reference control in enzymatic or cell-based signaling assays to establish dynamic range, Z′, and assay robustness. Typical workflows include titration curves (10-point, half-log) from high-concentration DMSO stocks.
  • Profiling: Employed in selectivity panels (kinome scans) and dose–response profiling across cell lines to map sensitivity landscapes. Ensure DMSO-matched vehicle controls and confirm compound stability over assay time.

Non-synthetic but practical tips:

  • Prepare fresh working dilutions immediately prior to use to minimize adsorption and degradation.
  • Include counter-screens for off-target readouts (e.g., cytotoxicity, reporter interference) to ensure on-mechanism interpretations.

Note: The manufacturer applications field for this listing is blank; the above points derive from general literature context for small-molecule kinase probes and should be validated in your system.

Reaction Conditions

Not a synthetic reagent: This product is supplied as a finished small molecule for biological research. Specific chemical reaction conditions are therefore not applicable.

Assay and handling conditions (general guidance instead):

  • Stock preparation: Commonly 10–50 mM in anhydrous DMSO; vortex and sonicate gently if needed. Filter 0.2 µm prior to sensitive assays.
  • Working concentrations: Determined empirically via dose–response titrations; include DMSO-matched vehicle controls and consider time-dependence of effect.
  • Stability checks: Assess freeze–thaw stability by LC–MS/HPLC; minimize freeze–thaw cycles by aliquoting.
  • Adsorption mitigation: Use low-binding tips/plates; pre-wet plastics with DMSO-containing buffer to reduce loss at low nM concentrations.

If you intend to use GDC-0879 in chemical reactions (e.g., derivatization to make probes), all conditions must be developed de novo for your target transformation. No item-specific reaction conditions are provided or implied here.

Safety and Handling

Safety data specific to this item are not listed here. Always review the product SDS before handling.

  • GHS Classification: Not specified for this item; refer to SDS.
  • Signal Word / Pictograms / H-Statements: Not specified for this item; refer to SDS.

General laboratory precautions for small-molecule kinase inhibitors:

  • PPE: Use lab coat, safety glasses, and appropriate chemically resistant gloves (e.g., nitrile). Avoid skin contact and inhalation of dust.
  • Engineering controls: Handle powders in a fume hood or ventilated enclosure to minimize particulate exposure. Use balance enclosures for weighing.
  • Avoid: Generating dust/aerosols; contact with strong oxidizers; uncontrolled heating. In absence of thermal data, avoid temperatures >60 °C.
  • First aid (overview; defer to SDS): If inhaled, move to fresh air; if on skin, wash with soap and water; if in eyes, rinse cautiously with water for several minutes; if ingested, seek medical advice. Provide SDS to medical responders.
  • Environmental: Prevent releases to drains. Collect waste as halogen-free organic solid/solution waste per institutional protocols.
  • Special considerations: Bioactive molecules can have potent cellular effects at low concentrations; minimize exposure and cross-contamination. Clean tools and surfaces thoroughly after use.

Shipping/Storage from product data:

  • Shipped In: Ice chest + ice pads (product data).
  • Storage: Store at −20 °C (product data). Protect from light and moisture to preserve integrity (general best practice).
Solvent Selection

Use case: preparation of analytical and biological assay stocks for a drug-like, hydrophobic small molecule.

Primary choices (general guidance):

  • DMSO: Preferred for preparing concentrated master stocks (e.g., 10–50 mM) due to broad solvating power and assay compatibility at ≤0.1–0.2% v/v. Ensure anhydrous, inhibitor-free DMSO for stability.
  • DMF or NMP: Alternative high-boiling polar aprotic solvents for difficult solubilization; consider cytotoxicity and assay interference at higher carryover.
  • Aqueous buffers: Often require co-solvent (DMSO 0.1–1%) or solubilization aids (e.g., 0.5–2% v/v ethanol, 0.01–0.1% Tween-80) to prevent precipitation; verify biological tolerance.

Miscibility profile (general):

  • DMSO is miscible with water and many organics, simplifying serial dilutions. Ethanol can be used for quick intermediate stocks but monitor volatility and assay effects.

Selection tips:

  • Rank solvents by chemical stability of the compound (avoid strong nucleophiles/bases and reactive impurities), assay tolerance, and analytical detection needs.
  • Filter low-volume working solutions (0.2 µm PTFE or PVDF) to remove particulates prior to cell-based assays.

Comparative note (general):

  • For long-term stocks, DMSO at −20 °C in amber vials with inert headspace minimizes hydrolysis/oxidation. For in vivo-adjacent method development (non-clinical), consider PEG400/propylene glycol cosolvent systems; confirm compatibility with your model. All choices should be validated experimentally for this specific item.
Storage and Reconstitution

Storage (from product data):

  • Store at −20 °C.
  • Shipped in an ice chest with ice pads.

General best practices for bioactive small molecules:

  • Protect from light and moisture. Store as a dry solid in an amber, tightly sealed container with desiccant where feasible.
  • After first opening, promptly prepare aliquots to minimize headspace and moisture ingress.

Reconstitution (general guidance; not a specification):

  • Solvent: Anhydrous DMSO is typically used to prepare concentrated stocks (e.g., 10–50 mM), subject to actual solubility of your lot. If aqueous stocks are required, dilute the DMSO stock into buffer slowly with mixing to avoid precipitation; maintain final DMSO at levels compatible with your assay.
  • Filtration: For sensitive assays, pass working solutions through a 0.2 µm PTFE/PVDF filter.
  • Aliquoting: Dispense single-use aliquots (e.g., 10–50 µL) in low-bind tubes. Avoid repeated freeze–thaw cycles.

Stability monitoring:

  • Track storage duration and freeze–thaw count. Verify integrity periodically by HPLC/LC–MS (no item-specific stability data are provided here).

Disposal:

  • Dispose of unused solutions and materials as organic chemical waste per institutional and regulatory requirements.

Note: Where any parameter above is critical to your workflow, confirm with the item’s CoA and your in-house validation.

Structure and Identity

Brief overview: GDC-0879 is listed as a small-molecule library member (Moligand grade) for research screening and chemical biology applications.

  • SKU: G127893
  • Product Name: GDC-0879
  • CAS: 905281-76-7 (product data)
  • PubChem CID: 11717001 (product data; consult for public-domain structural details — literature)
  • InChIKey: 61719 (as provided; note this appears truncated vs typical 27-character InChIKey formats)
  • SMILES: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.

Structural features (general, literature context):

  • GDC-0879 is reported in the literature as a drug-like, heteroatom-rich kinase inhibitor scaffold. Public sources depict polycyclic/aromatic motifs with heteroatoms consistent with kinase hinge-binding pharmacophores. Exact atom connectivity and stereochemistry should be verified against an authenticated CoA/SDS.

2D structure description (general):

  • Literature depictions show fused and/or linked aromatic rings with hydrogen-bond donor/acceptor functionality arranged to engage ATP-binding sites. Without an item-specific structure in this listing, users should consult validated references (e.g., PubChem CID 11717001) and the item’s CoA for definitive identity.

Identity verification best practices:

  • Confirm by LC–MS (m/z of [M+H]+), 1H/13C NMR, and HPLC purity per your laboratory acceptance criteria.
  • Cross-check CAS and catalog identifiers prior to use in critical experiments.
Synthetic Utility

This listing is for a finished bioactive small molecule intended as a research tool; it is not primarily supplied as a synthetic building block.

General synthetic context (literature):

  • Molecules in the GDC-0879 class typically arise from convergent assembly of heteroaromatic cores, followed by diversification to tune kinase selectivity and physicochemical properties. Common operations may include palladium-catalyzed aryl–aryl couplings, amide/urea formations, and heteroaryl substitutions.

Utility in synthesis labs (practical points):

  • Derivatization: Researchers may derivatize the scaffold (e.g., install photoaffinity or biotin tags) to generate chemical probes for target engagement studies (CETSA, pull-downs). Such work requires independent route development; no procedures are specified for this item.
  • Analytical benchmarking: Use as a retention-time/UV-response comparator during method development for related analog series.

Retrosynthetic insight (conceptual):

  • The presence of multiple aromatic rings and heteroatoms suggests disconnections to commercially available heteroaryl building blocks and use of chemoselective cross-couplings.

Important caveat:

  • No reactive handles, salt form, or specific functional-group data are provided in this listing. Any synthetic modification plans should begin with full structural confirmation from authenticated references and in-house analytics.
Target Specificity

Only include information provided in the product data for this listing.

  • Target/Pathway: Not specified for this item; refer to CoA/Spec Sheet.
  • Species reactivity: Not specified for this item; refer to CoA/Spec Sheet.
  • Assay-validated activities: Not specified for this item; refer to CoA/Spec Sheet.

Note: While the literature discusses GDC-0879 in the context of kinase pathway modulation, no target specificity is claimed in this catalog entry. Users should consult peer-reviewed sources and validate target engagement experimentally in their systems.

Domande frequenti

What is the purity of this product?
This product is supplied at ≥96% purity (chemical assay). Lot-specific values are stated on the Certificate of Analysis.
What is Moligand??
Moligand? is one of Aladdin Scientific's premium product lines, formulated for high-purity applications across multiple workflows. Compared to standard grades in the same workflow, Moligand? products typically offer tighter specifications, more rigorous QC, and stronger lot-to-lot consistency.
How should this product be stored?
Store at ?20 °C. Freezer storage is required to maintain the specified shelf life.
How is this product shipped?
This product ships in an insulated container with ice pads. Unpack on arrival and transfer it to the storage condition stated above.
What are the CAS number, molecular formula and molecular weight?
The CAS Number is 905281-76-7, the molecular formula is C19H18N4O2, and the molecular weight is 334.37 g/mol. InChIKey DEZZLWQELQORIU-RELWKKBWSA-N.
What documentation is provided?
Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.

Hai bisogno di aiuto per scegliere la qualità?

La nostra guida alla selezione delle qualità copre purezza, stato dello stabilizzatore e idoneità all'applicazione per tutte le varianti del nostro catalogo.

Visualizza la guida alle qualità Moligand™ →

Desidera che le inviamo un messaggio quando avremo sconti disponibili?

Ricordamelo più tardi

Grazie! Controlli la sua casella di posta per confermare.

Ops! Le notifiche sono disabilitate.